SmithKline Seeks Injunction Against Watson Nicotine Gum Labeling
This article was originally published in The Tan Sheet
Executive Summary
SmithKline Beecham Consumer Healthcare alleges copyright infringement of the company's Nicorette smoking cessation gum in a lawsuit filed against Watson Pharmaceuticals and its subsidiaries, Watson Laboratories and Circa Pharmaceuticals, Aug. 26.
You may also be interested in...
Hatch/Waxman Act Allows Potential Copyright Infringement - Court
A New York City federal appeals court unanimously ruled in favor of Watson Pharmaceuticals April 4, lifting a preliminary injunction against the sale of its generic OTC nicotine polacrilex gum and dismissing SmithKline Beecham Consumer Healthcare's copyright infringement action.
Hatch/Waxman Act Allows Potential Copyright Infringement - Court
A New York City federal appeals court unanimously ruled in favor of Watson Pharmaceuticals April 4, lifting a preliminary injunction against the sale of its generic OTC nicotine polacrilex gum and dismissing SmithKline Beecham Consumer Healthcare's copyright infringement action.
Hatch/Waxman Act Allows Potential Copyright Infringement - Court
A New York City federal appeals court unanimously ruled in favor of Watson Pharmaceuticals April 4, lifting a preliminary injunction against the sale of its generic OTC nicotine polacrilex gum and dismissing SmithKline Beecham Consumer Healthcare's copyright infringement action.